ABUS vs LI · P/E 5.4, rev $6.2M vs P/E 24, rev $16.06B
Arbutus Biopharma Corp (ABUS) versus Li Auto Inc (LI) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Li Auto Inc (LI) is a auto manufacturers company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported LI revenue for 2025-12-31 was $16.06B. Net income was $162.9M. Revenue was down 18.8% from 2024-12-31 to 2025-12-31. LI currently screens at market cap $26.62B and trailing P/E 24.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. LI currently screens at market cap $26.62B and trailing P/E 24.2.
Not investment advice. Open the ABUS and LI stock pages for the full models.
Not investment advice.